AP NEWS

Gamma-Delta (γδ) T Cell Therapy Combined With Checkpoint Inhibition Shows Potential Synergies in Vitro for Treatment of Glioblastoma

November 15, 2018

Promising data from gamma-delta (γδ) T cell therapy in combination with checkpoint inhibitors to be presented at 2018 Society for Neuro-Oncology annual meeting

NEW YORK, Nov. 15, 2018 (GLOBE NEWSWIRE) -- Incysus Therapeutics, Inc. (“Incysus”), a biopharmaceutical company focused on delivering an innovative gamma-delta (γδ) T cell immunotherapy for the treatment of cancers, today announced that promising data from a pilot in vitro study combining checkpoint inhibitors (CKI) with gamma-delta (γδ) T cell therapy will be presented during the 23rd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) in New Orleans.

A poster entitled, “Engineered-drug resistant gamma-delta (γδ) T cells combined with immune checkpoint blockade augmented killing of cancer cells,” will be presented Friday, November 16, at 7:30 pm CT in the Grand Ballroom of the Sheraton Hotel. The abstract for this poster is available online here: https://doi.org/10.1093/neuonc/noy148.518

“We continue to examine novel combinations to drive responses in solid tumor cancers. These preclinical results point to the potential application of checkpoint inhibition to simultaneously augment effector function and persistence of MGMT-gene-modified γδ T Cells as Drug-Resistant Immunotherapy, while simultaneously blocking tumor-derived PD-L1 expression upregulated during chemotherapy,” said Lawrence S. Lamb, Ph.D., Professor of Medicine and Director of the Cell Therapy Laboratory at the University of Alabama at Birmingham (UAB) and Scientific Co-Founder of Incysus.

About the Society for Neuro-OncologyThe Society for Neuro-Oncology is a multidisciplinary organization dedicated to promoting advances in neuro-oncology through research and education.

Now in its twenty fourth year, the Society continues to grow and mature as the premier North American organization for clinicians, basic scientists, nurses and other health care professionals whose focus is central nervous system tumors in children and adults.

About Incysus Therapeutics, Inc.Incysus is focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified gamma-delta (γδ) T cells, the Company’s technology addresses the challenges that immunotherapies face targeting cold, low mutation cancers. Incysus’ immuno-oncology programs include activated and gene-modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells. Since the Company’s inception in early 2016, Incysus has filed two Investigational New Drug applications (IND) and has initiated several cancer programs in early pre-clinical stages. The Company’s first program is targeted to leukemia and lymphoma patients and the IND related to this program was accepted by the FDA in late 2017. The Company’s second program is targeted to treat patients with newly-diagnosed glioblastoma (GBM). In collaboration with the University of Alabama at Birmingham (UAB), Incysus has advanced its technology and expects to begin both Phase 1 trials in the first half of next year. For more information, visit www.incysus.com.

Contact:Incysus Therapeutics, Inc.(646) 820-8474info@incysus.com

AP RADIO
Update hourly